Gsk (GSK) Other financing activities (2009 - 2026)

Gsk (GSK) posted quarterly Other financing activities of $2.7 million for Q2 2026, down 99.87% quarter-over-quarter from $2.1 billion in Q1 2026.

Gsk (GSK) Other financing activities (2009 - 2026) Analysis & Trends

Gsk's Other financing activities history runs 18 years deep, the most recent figure standing at $2.7 million for Q2 2026.

In Q2 2026, Other financing activities changed N/A year-over-year to $2.7 million; the TTM figure through Jun 2026 stood at $2.3 billion (changed N/A YoY), while the FY2024 annual figure was $11.5 million, up 32.13% from the prior year.
Other financing activities for Q2 2026 stood at $2.7 million, down from $2.1 billion in the prior quarter.
The five-year high for Other financing activities was $2.1 billion in Q1 2026, with the low at -$36.5 million in Q1 2025.
The 5-year median for Other financing activities is $9.5 million (2023), against an average of $234.3 million.
Peak annual rise in Other financing activities reached 12232.65% in 2025, while the deepest fall reached 175.77% in 2025.
Gsk's Other financing activities stood at $10.7 million in 2022, then declined by 20.74% to $8.5 million in 2023, then slumped by 84.92% to $1.3 million in 2024, then surged by 12232.65% to $158.3 million in 2025, then tumbled by 98.3% to $2.7 million in 2026.
Business Quant data shows GSK's Other financing activities at $2.7 million in Q2 2026, $2.1 billion in Q1 2026, and $158.3 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn
10	Sanofi	55.07 Bn	47.69 Bn	10.79 Bn

Download Data